Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer

The purpose of this study is to evaluate whether treatment with the investigational drug OK-1 in combination with paclitaxel can reduce tumor burden in patients with advanced or recurrent endometrial cancer (A/R-EC).

Trial Details

NCT ID
NCT07737795
Phase
PHASE2
Sponsor
University of Oklahoma
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • OK-1 & Paclitaxel
Locations (sample)
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643

Key Eligibility Criteria

  • At least 18 years-of-age at the time of signature of the informed consent form (ICF).
  • Histologically documented carcinoma of the endometrium, including endometrioid, serous, mixed adenocarcinoma, clear-cell carcinoma, or carcinosarco…
  • Must have pre-treatment archival tissue.
  • Measurable disease by RECIST v1.1 is required for the phase 2 portion of the study. Patients with accessible disease are eligible for the safety le…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →